Tenaya Therapeutics (TNYA) Research & Development (2020 - 2026)

Tenaya Therapeutics has reported Research & Development for 7 years, with the latest figure at $16.6 million in Q2 2026.

• On a quarterly basis, Research & Development fell 4.42% year-over-year to $16.6 million in Q2 2026; TTM through Jun 2026 was $61.6 million, a 20.49% decrease from a year earlier, with the FY2025 full-year figure at $68.6 million, down 20.91% from the prior year.
• Research & Development was $16.6 million for Q2 2026 at Tenaya Therapeutics, up from $14.8 million in the prior quarter.
• The five-year high for Research & Development was $26.5 million in Q2 2023, with the low at $14.8 million in Q4 2025.
• Average Research & Development over 5 years is $21.1 million, with a median of $21.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Research & Development jumped 151.88% in 2022, then dropped 29.57% in 2026.
• Over 5 years, Research & Development stood at $25.7 million in 2022, then slipped by 11.2% to $22.9 million in 2023, then slipped by 18.27% to $18.7 million in 2024, then decreased by 20.82% to $14.8 million in 2025, then rose by 12.2% to $16.6 million in 2026.
• The last three Research & Development figures came in at $16.6 million (Q2 2026), $14.8 million (Q1 2026), and $14.8 million (Q4 2025), per Business Quant data.